Financing ·
Definium Therapeutics, Inc. entered into an underwriting agreement on June 23, 2026, for a public offering of…
DFTXDefinium Therapeutics, Inc.
Definium Therapeutics, Inc. entered into an underwriting agreement on June 23, 2026, for a public offering of 20,588,236 common shares at $34.00 per share. Underwriters J.P. Morgan Securities LLC, Jefferies LLC, Leerink Partners LLC, and BofA Securities, Inc. fully exercised an option to purchase an additional 3,088,235 shares on June 24, 2026. The company expects gross proceeds of approximately $805 million and net proceeds of approximately $758 million. Net proceeds are earmarked for research and development, potential commercialization of DT120 ODT, and general corporate purposes. The offering is expected to close on June 25, 2026. Definium Therapeutics, Inc. is a biotechnology company focused on product candidate development.